Loading
FCGR2B (Low affinity immunoglobulin gamma Fc region receptor II-b) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer and Non-Hodgkin lymphoma.
Receptor for the Fc region of complexed or aggregated immunoglobulins gamma. Low affinity receptor. Involved in a variety of effector and regulatory functions such as phagocytosis of immune complexes and modulation of antibody production by B-cells.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant. Open Targets scores its association with cancer at 0.66 (direct and indirect evidence; datatypes literature 0.95, animal model 0.42, genetic association 0.36, somatic mutation 0.95). IntOGen calls it a driver in 1 cohort (0 activating, 1 loss-of-function), covering Malignant Lymphoma.
In plain words · FCGR2B (Low affinity immunoglobulin gamma Fc region receptor II-b) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer and Non-Hodgkin lymphoma.
FCGR2B (Low affinity immunoglobulin gamma Fc region receptor II-b) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer and Non-Hodgkin lymphoma.
Receptor for the Fc region of complexed or aggregated immunoglobulins gamma. Low affinity receptor.
No product in this corpus aims at FCGR2B yet. Because the protein is lost rather than overactive, drugs either restore its function or exploit the weakness its loss leaves (synthetic lethality).
Tumour-specific alteration: the catalogues call it a tumour suppressor (IntOGen finds it knocked out more often than chance); what a medicine would aim at or exploit is the altered form or its loss, absent from normal cells; no corpus medicine is aimed at it yet. HPA FCGR2B: RNA tissue enriched (placenta 378 nTPM); high antibody staining in 1 normal tissue. Distribution: 2 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Breast cancer (all types), Lymphoma); Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 6 of scripts/fetch-target-specificity.ts.)
Sources: UniProt P31994; CIViC gene FCGR2B; IntOGen FCGR2B; Human Protein Atlas FCGR2B tissue; Open Targets ENSG00000072694 associations
First described 1989. Earliest sequence paper UniProt cites for the protein: Stuart S.G. et al, EMBO J, 1989, "Human IgG Fc receptor (hFcRII; CD32) exists as multiple isoforms in macrophages, lymphocytes and IgG-transporting placental epithelium". Source.
Sources: HGNC HGNC:3618 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P31994 (protein name, function text, keywords and locations (REST API)); CIViC gene FCGR2B (1 evidence items, 0 assertions, 1 variants; diseases: Breast Cancer (GraphQL API, CC0)); Open Targets ENSG00000072694 (association with cancer (MONDO_0004992) 0.66; per-cancer scores at or above 0.5: breast cancer 0.50 (GraphQL API, CC0)); IntOGen FCGR2B (driver in 1 cohort (Act 0, LoF 1); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Receptor for the Fc region of complexed or aggregated immunoglobulins gamma. Low affinity receptor. Involved in a variety of effector and regulatory functions such as phagocytosis of immune complexes and modulation of antibody production by B-cells. Binding to this receptor results in down-modulation of previous state of cell activation triggered via antigen receptors on B-cells (BCR), T-cells (TCR) or via another Fc receptor. Isoform IIB1 fails to mediate endocytosis or phagocytosis. Isoform IIB2 does not trigger phagocytosis. Location: Cell membrane (UniProt). Locus 1q23.3 (HGNC).
RNA: tissue enriched (placenta 378 nTPM), detected in all normal tissues.
Medium: Bone marrow, Lymph node, Spleen, Tonsil.
No cancer stained high; medium in thyroid cancer.
HPA FCGR2B tissue · HPA FCGR2B pathology · HPA protein class: CD markers, FDA approved drug targets
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"FCGR2B" OR ABSTRACT:"FCGR2B" OR TITLE:"Fc gamma receptor IIb" OR ABSTRACT:"Fc gamma receptor IIb" OR TITLE:"Low affinity immunoglobulin gamma Fc region receptor II-b" OR ABSTRACT:"Low affinity immunoglobulin gamma Fc region receptor II-b" OR TITLE:"CD32" OR ABSTRACT:"CD32" OR TITLE:"CD32B" OR ABSTRACT:"CD32B" OR TITLE:"FcgammaRIIb" OR ABSTRACT:"FcgammaRIIb") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about FCGR2B, not a curated reading list.